CPH · NOVO-B.CO
Novo Nordisk A/S
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
Loading market information…
CPH · AMBU-B.CO · DKK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 03:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · DKK. Historical prices are not a forecast.
Ambu A/S’s quoted price sits in the lower half of its reported 52-week range, 24.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ambu A/S’s forward annual dividend is DKK 0.41 per share, paid annual. The forward yield is 0.52% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Ambu A/S’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of DKK 0.87. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ambu A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1937 and headquartered in Ballerup, Denmark, Ambu A/S is a global medical technology company specializing in the design, manufacture, and sale of advanced medical devices. The company serves hospitals, clinics, and emergency services worldwide, providing essential healthcare solutions across key disciplines such as visualization, anesthesia, and patient monitoring and diagnostics. Their extensive product portfolio includes sophisticated endoscopy equipment like bronchoscopes and dedicated monitors. For neurology, Ambu offers EEG and EMG electrodes, as well as tools for EMG-guided injections and intraoperative monitoring systems. Cardiology solutions feature ECG electrodes. A substantial portion of their offerings is dedicated to airway management and anesthesia, comprising specialized bronchoscopes, video laryngoscopes, various intubation tubes (double and single lumen), endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitation devices. Additionally, Ambu provides critical emergency and training products, including extrication collars, CPR breathing barriers, and training manikins.
Latest available per-share figures in DKK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| May 7, 2025 |
| DKK 0.71-5.33% vs estimate |
| DKK 1.55B+3.69% vs estimate |
| Q1 2025 | Jan 30, 2025 | DKK 0.68+51.11% vs estimate | DKK 1.51B-4.43% vs estimate |
|---|
| Q4 2024 | Nov 5, 2024 | -DKK 0.51-202.0% vs estimate | DKK 1.39B+1.84% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
DKK 3,788.00-DKK 80.00 (-2.07%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
DKK 477.00-DKK 1.50 (-0.31%)
Coloplast A/S’s quoted price sits in the lower half of its reported 52-week range, 24.45% below the high.
DKK 366.00+DKK 3.20 (+0.88%)
Demant A/S’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
DKK 246.60+DKK 3.00 (+1.23%)
ALK-Abelló A/S’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
DKK 54.45+DKK 1.65 (+3.13%)
H. Lundbeck A/S’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
DKK 247.80-DKK 7.80 (-3.05%)
Bavarian Nordic A/S’s quoted price sits in the upper half of its reported 52-week range, 3.58% below the high.
